These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24837258)

  • 1. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.
    Sharma A; Einstein AJ; Vallakati A; Arbab-Zadeh A; Walker MD; Mukherjee D; Homel P; Borer JS; Lichstein E
    Am J Cardiol; 2014 Jun; 113(11):1815-21. PubMed ID: 24837258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis.
    Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S
    Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.
    Mak A; Cheung MW; Ho RC; Cheak AA; Lau CS
    BMC Musculoskelet Disord; 2009 Sep; 10():113. PubMed ID: 19772579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
    Loke YK; Jeevanantham V; Singh S
    Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and risk of atrial fibrillation: a meta-analysis.
    Kim SY; Kim MJ; Cadarette SM; Solomon DH
    Arthritis Res Ther; 2010; 12(1):R30. PubMed ID: 20170505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
    Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
    PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
    Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
    Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.
    Prescrire Int; 2011 Apr; 20(115):96-7. PubMed ID: 21648212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
    Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
    Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis.
    Bhuriya R; Singh M; Molnar J; Arora R; Khosla S
    Int J Cardiol; 2010 Jul; 142(3):213-7. PubMed ID: 20051297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bisphosphonates and atrial fibrillation.
    Majumdar SR
    BMJ; 2008 Apr; 336(7648):784-5. PubMed ID: 18334526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of bisphosphonates on the risk of atrial fibrillation.
    Howard PA; Barnes BJ; Vacek JL; Chen W; Lai SM
    Am J Cardiovasc Drugs; 2010; 10(6):359-67. PubMed ID: 21090829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
    Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA
    BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study.
    Erichsen R; Christiansen CF; Frøslev T; Jacobsen J; Sørensen HT
    Br J Cancer; 2011 Sep; 105(7):881-3. PubMed ID: 21878939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women: A nationwide population-based analysis.
    Yang HY; Huang JH; Chiu HW; Lin YK; Hsu CY; Chen YJ
    Medicine (Baltimore); 2018 Oct; 97(43):e12947. PubMed ID: 30412111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis].
    Wang H; Hu ZH; Chen L; Pan Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):680-682. PubMed ID: 29263512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.